NEW YORK, Nov. 1, 2022 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation into potential securities claims on behalf of shareholders of Instil Bio, Inc. (NASDAQ: TIL) arising from allegations that Instil Bio may be providing materially misleading business information to the investing public Has .

SO WHAT: If you have purchased Instil Bio securities, you may be entitled to compensation without payment of out-of-pocket expenses or costs through a contingency fee arrangement. Law firm Rosen is preparing a class action lawsuit to recover investor losses.

WHAT TO DO NEXT: To participate in the prospective class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=9501 or call Phillip Kim, Esq. toll free at 866-767-3653 or by email [email protected] or [email protected] for information about the Class Action.

WHAT IS THIS ABOUT: On October 31, 2022, prior to the close of trading, Instil Bio issued a press release titled “Instil Bio Announces Voluntary Suspension of Enrollment in Ongoing Manufacturing-Related Clinical Trials,” announcing the suspension and stating that the suspension was due to “a recent decrease the rate of successful manufacture of ITIL-168, resulting in the inability to treat some patients whose individual ITIL-168 product was not successfully manufactured.” In addition, the company announced that “[a]Although no manufacturing defects have been observed to date in the ongoing Phase 1 study of ITIL-306, the company has voluntarily suspended enrollment in this study as part of its overall manufacturing analysis.” to provide an update of the manufacturing analysis in the first quarter of 2023”.

As a result of this news, Instil Bio’s stock fell $1.95 per share, or 37%, to close at $3.30 per share on October 31, 2022.

WHY ROSES LAW: We encourage investors to select qualified advisors with a track record in leadership positions. Exhibiting companies often do not have comparable…